Allogeneic ‘off‐the‐shelf’ <scp>SARS</scp>‐<scp>C</scp>o<scp>V</scp>‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ diseaseAndrea Henden, Corey Smith, Laëtitia Le Texier et al.|Clinical & Translational Immunology|2025Cited by 1
A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signaturesCorey Smith, Rajiv Khanna, Vijayendra Dasari et al.|Nature Communications|2026Cited by 1
TCR signatures following SARS-CoV-2 infection correlate with clinical symptoms and post-acute sequelae of COVID-19Corey Smith, Rajiv Khanna, Katie E. Lineburg et al.|Research Square|2023Cited by 0
A Multidimensional Workflow Profiling of Allogeneic EBV-Specific T-cell Therapies Reveals Potency-Linked SignaturesRajiv Khanna, Pamela Mukhopadhyay, Corey Smith et al.|Research Square|2025Cited by 0